Cytel: Kyle Wathen, VP of scientific strategy and innovation
Clinical trial tech provider Cytel has named Kyle Wathen vice president of scientific strategy and innovation. He brings to the company more than two decades of adaptive clinical trial design, as well as major contributions to the first adaptive platform trial, I-SPY2.
“The growing adoption of complex designs – facilitated by enabling tools like East and Solara – is a momentous step forward for the industry,” said Wathen. “I’m dedicated to further elevating Cytel’s innovative design arsenal and empowering customers to carve a smoother, more efficient path to market.”
